<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Misoprostol as a single agent for medical termination of pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Misoprostol as a single agent for medical termination of pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Misoprostol as a single agent for medical termination of pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monica Dragoman, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caitlin Shannon, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beverly Winikoff, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jody Steinauer, MD, MAS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Medical methods for pregnancy termination are safe, effective, and feasible alternatives to surgical methods (ie, uterine aspiration, dilation and evacuation [D&amp;E]) and expand a patient's treatment options [<a href="#rid1">1</a>]. </p><p>For patients undergoing medication abortion, combined treatment with <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> followed by <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> is more effective than treatment with misoprostol alone, and thus is considered the gold standard for medication abortion [<a href="#rid2">2,3</a>]. However, misoprostol-alone regimens may be the treatment of choice in settings in which mifepristone is not available or is too costly. In particular, misoprostol is commonly used as a single agent for second-trimester induced abortion in the United States and many other parts of the world [<a href="#rid4">4,5</a>].</p><p>This topic review will discuss use of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> as a single agent for medical termination of pregnancy. Use of <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> plus misoprostol, in addition to other medical and surgical approaches to pregnancy termination, and use of misoprostol for pregnancy loss or labor induction are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5442.html" rel="external">"Pregnancy loss (miscarriage): Clinical presentations, diagnosis, and initial evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5398.html" rel="external">"Induction of labor: Techniques for preinduction cervical ripening"</a>.)</p><p></p><p class="headingAnchor" id="H2891291839"><span class="h1">PREPROCEDURE CONSIDERATIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to medication abortion with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> alone are similar to those for medication abortion with misoprostol plus <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Contraindications'</a> and  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Indications and contraindications'</a>.)</p><p class="headingAnchor" id="H3593952241"><span class="h2">Patients with a uterine scar</span><span class="headingEndMark"> — </span>Presence of a uterine scar is <strong>not</strong> a contraindication for <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>. However, as pregnancy advances, regimens with lower cumulative misoprostol doses (ie, lowest dose, longest dosing interval, lowest number or total doses) [<a href="#rid6">6,7</a>], or a surgical procedure (ie, uterine aspiration, dilation and evacuation [D&amp;E]) may be preferred, especially for patients with a history of multiple cesarean births or other extensive uterine surgery (eg, multiple myomectomies). (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'How to choose'</a> and  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Choosing dilation and evacuation versus induction termination'</a>.)</p><p>Although rare, case reports have described uterine rupture during first- and second-trimester pregnancy termination with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> [<a href="#rid8">8-19</a>]. The risk of rupture may increase with increasing gestational age, particularly in the late second trimester [<a href="#rid13">13</a>], and may be higher in patients with classical, T-shaped, or transfundal uterine incisions. However, uterine rupture can also occur in patients without a uterine scar. Other factors associated with uterine rupture include advanced gestational age, high gravidity (≥3 pregnancies) [<a href="#rid14">14,15</a>], uterine anomalies, and use of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> in addition to misoprostol [<a href="#rid14">14,15</a>]. </p><p>There are no high-quality data regarding the risk of uterine rupture with use of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> for first- or second-trimester pregnancy termination. In a systematic review including 15 studies and 512 pregnant patients receiving misoprostol for induction in the second trimester, the risk of uterine rupture was higher among those with two or more compared with no previous cesarean births (2.5 versus 0.08 percent, relative risk 17.6, 95% CI 3-102.8) [<a href="#rid20">20</a>]. However, data are limited, and risk of rupture remains unquantified because studies often exclude patients with scarred uteri or have low numbers of patients with different types of uterine scars. </p><p>Clinical manifestations of uterine rupture following medical termination of pregnancy are variable and include severe and persistent abdominal pain, hypotension (ranging from subtle to severe [hypovolemic shock]), cessation of uterine contractions, uterine tenderness, or loss of fetal station on digital examination in the second trimester. Hematuria may occur if the rupture extends to the bladder. Vaginal bleeding is not a cardinal symptom, as it may be modest, despite major intraabdominal hemorrhage. Ultrasound examination may confirm the diagnosis [<a href="#rid11">11,21</a>]. Rupture or dehiscence is managed with exploratory laparotomy, with either uterine repair (and removal of the pregnancy tissue) or hysterectomy. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/87237.html" rel="external">"Uterine rupture: After previous cesarean birth"</a> and  <a class="medical medical_review" href="/d/html/14210.html" rel="external">"Uterine rupture: Unscarred uterus"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Planning and preparation</span><span class="headingEndMark"> — </span>General procedure planning, as well as preparation prior to misoprostol-only medication abortion, includes: </p><p class="bulletIndent1"><span class="glyph">●</span>A nondirective discussion of alternatives (abortion or continuing pregnancy with parenting or adoption). (See  <a class="medical medical_review" href="/d/html/114587.html" rel="external">"Counseling in abortion care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling regarding procedure type (medication or surgical) and the risks and benefits of each. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Choice of procedure'</a> and  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Choosing dilation and evacuation versus induction termination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of gestational age. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Determining gestational age'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The role of laboratory testing for hemoglobin or hematocrit, RhD typing (and administration of <a class="drug drug_general" data-topicid="9858" href="/d/drug information/9858.html" rel="external">anti-D immune globulin</a> to D-negative individuals)  (<a class="graphic graphic_table graphicRef140124" href="/d/graphic/140124.html" rel="external">table 1</a>), and chlamydia and/or gonorrhea. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plan for contraception. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Plan for contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling regarding warning signs and when to call their provider  (<a class="graphic graphic_table graphicRef126344" href="/d/graphic/126344.html" rel="external">table 2</a>). </p><p></p><p>Prophylactic antibiotics and cervical dilators are typically <strong>not</strong> used for medication (ie, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> with or without <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a>) abortion. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Cervical dilation and preparation'</a> and  <a class="medical medical_review" href="/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination", section on 'Cervical dilation'</a>.)</p><p>A discussion about indications for induced fetal demise is also provided separately. (See  <a class="medical medical_review" href="/d/html/6819.html" rel="external">"Induced fetal demise"</a>.)</p><p class="headingAnchor" id="H669828910"><span class="h1">PROTOCOL</span><span class="headingEndMark"> — </span>The US Food and Drug Administration (FDA) approved <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a>, in a regimen with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, for early abortion [<a href="#rid22">22</a>]. However, the off-label use of misoprostol as a single agent for medical termination of pregnancy is endorsed by the World Health Organization (WHO) and professional medical associations including the American College of Obstetricians and Gynecologists (ACOG) and the Society for Family Planning (SFP) and is widely used for this purpose in the United States and globally [<a href="#rid23">23-25</a>]. </p><p class="headingAnchor" id="H3579080281"><span class="h2">Accepted regimens</span><span class="headingEndMark"> — </span>Accepted regimens for medication abortion with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> alone, as recommended by the WHO and the International Federation of Gynecology and Obstetrics (FIGO), are listed in the table  (<a class="graphic graphic_table graphicRef128440" href="/d/graphic/128440.html" rel="external">table 3</a>). </p><p>The WHO guidelines do not specify a dosing interval for pregnancies &lt;12 weeks but note that repeat doses of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> can be considered to achieve a success with the abortion process [<a href="#rid26">26</a>]. The FIGO recommendations offer additional insight into clinical regimens across a wider array of gestational age thresholds [<a href="#rid27">27</a>]. All gestational ages refer to weeks of amenorrhea. Other professional medical associations, including the ACOG and the National abortion federation (NAF), have guidelines that are consistent with these regimens [<a href="#rid24">24,28,29</a>].</p><p>If fetal and placental expulsion has not occurred at 24 to 40 hours, the protocol may be repeated, or a uterine evacuation procedure may be performed [<a href="#rid30">30-32</a>]. There are insufficient data on the safety and effectiveness of using alternative uterotonics (eg, other prostaglandins, <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a>) [<a href="#rid33">33</a>], and precautions should be taken to avoid uterine hyperstimulation. (See <a class="local">'Patients with a uterine scar'</a> above.)</p><p class="headingAnchor" id="H3326303561"><span class="h2">Management of placenta</span><span class="headingEndMark"> — </span>For patients beyond 12 weeks of gestation, expulsion of the placenta usually occurs shortly after the fetus is delivered but may take as long as 30 minutes to four hours after delivery of the fetus [<a href="#rid34">34</a>]. If two or more hours have passed and the placenta has not delivered, an infusion of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> 10 units in 500 mL of normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> administered intravenously at a rate of 20 to 30 drops per minute may be given. Repeat doses of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> can be continued where oxytocin is not available [<a href="#rid33">33</a>]. Manual or surgical removal of the placenta may be required in selected cases (eg, placenta does not deliver after medical management, excessive bleeding, signs of intrauterine infection). (See  <a class="medical medical_review" href="/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination", section on 'Retained placenta'</a>.)</p><p>After expulsion, the placenta is examined to ensure the entire placenta has been expelled. </p><p class="headingAnchor" id="H842434878"><span class="h1">DRUG ADMINISTRATION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> administration in pregnancy induces cervical softening and dilation and uterine contractions at all gestational ages, thereby facilitating uterine evacuation [<a href="#rid35">35</a>]. The potency of misoprostol's effect on uterine contractions, however, varies with gestational age, as well as route of administration, dose, dosing interval, and cumulative dose.</p><p class="headingAnchor" id="H754406781"><span class="h2">Setting</span><span class="headingEndMark"> — </span>Early in pregnancy (≤11 weeks of gestation), <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> is typically self-administered by the patient at home [<a href="#rid36">36</a>]. Patients are counseled about expected symptoms (eg, vaginal bleeding, abdominal pain, nausea, vomiting, fevers) and given a telephone number to call with questions, in case of an emergency (eg, bleeding that does not decrease after pregnancy tissue is passed, soaking two maxi pads per hour for two consecutive hours), or if they do not think they passed the pregnancy. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Counseling and informed consent'</a> and  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Expected symptoms'</a>.)</p><p>In the United States, for patients with pregnancies beyond 12 weeks, treatment is usually administered in a clinic or hospital setting. While complete expulsion is probable at such gestations, products of conception are examined to determine whether the abortion is complete. During treatment with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, the frequency and strength of uterine contractions are monitored. Practice varies, and monitoring may be with patient report, external palpation, or external tocodynamometry. Additional doses of misoprostol may be deferred if uterine contractions are strong and/or too frequent (&gt;3 contractions/10 min) [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Procedure setting'</a>.)</p><p class="headingAnchor" id="H862705210"><span class="h2">Route</span><span class="headingEndMark"> — </span>While <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> can be administered by buccal, sublingual, vaginal, oral, or rectal routes [<a href="#rid37">37-42</a>], <strong>buccal</strong>, <strong>sublingual</strong>, and <strong>vaginal</strong> routes of administration are preferred for most patients undergoing first- and second-trimester termination. Oral administration is no longer recommended as a primary route for medication abortion, except in very early pregnancy, as its effectiveness decreases with increasing gestational age [<a href="#rid43">43-45</a>]. In a meta-analysis of two randomized trials including 216 patients undergoing first-trimester medication abortion, those receiving oral compared with vaginal misoprostol had more incomplete abortions (19.5 versus 5.3 percent, relative risk 3.68, 95% CI 1.56-8.71), however, the certainty of this evidence was low [<a href="#rid46">46</a>]. Oral dosing was also associated with more frequent side effects (eg, nausea, diarrhea, fevers). </p><p>Pharmacokinetic profiles vary by route [<a href="#rid37">37,38,41,42</a>]. For example, sublingual administration creates high peaks in serum levels, sometimes causing very painful contractions and more frequent other side effects. However, all three of the most commonly used routes (ie, buccal, sublingual, vaginal) are effective [<a href="#rid43">43-63</a>], and provide regular and sustained uterine activity [<a href="#rid42">42</a>]. Practice varies, and the choice among these preferred routes depends on patient, provider, and institutional preference, and local abortion regulations. In settings where abortion is criminalized, vaginal <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> may be avoided as fragments of the pill can be present hours after placement and may be found during pelvic examinations. </p><p>Regimens that combine routes of administration (such as an initial vaginal dose of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> followed by oral or buccal routes) were previously used for some terminations after 12 weeks but are no longer recommended [<a href="#rid47">47</a>]. These mixed route protocols can be confusing and cumbersome to implement, and single-route regimens perform equally well [<a href="#rid64">64-68</a>]. </p><p>Additional evidence of route of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> administration is presented separately. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Misoprostol'</a>.)</p><p class="headingAnchor" id="H1192496432"><span class="h2">Dose and dosing interval</span><span class="headingEndMark"> — </span>Examples of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> dose and dosing intervals are listed in the table  (<a class="graphic graphic_table graphicRef128440" href="/d/graphic/128440.html" rel="external">table 3</a>). The sensitivity of the uterus to prostaglandins increases with gestational age [<a href="#rid35">35</a>]. For this reason, providers generally use decreasing amounts of misoprostol with increasing gestational age.</p><p>The optimal dose and dosing interval generates sufficient and sustained uterine activity while minimizing adverse effects [<a href="#rid36">36</a>]. Longer dosing intervals have the benefit of exposing a patient to a decreased risk of side effects. Conversely, shorter dosing intervals (closer to three hours) may be necessary to generate sufficient uterine activity, in particular if <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> is given via a route with a rapid rise and fall in serum levels (ie, oral and sublingual) [<a href="#rid38">38</a>]. Uterine hyperstimulation is rare, especially in the first trimester; however, the risk may increase with shorter dosing intervals.</p><p>In pregnancies at ≤12 weeks of gestation, one to three doses of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> are typically sufficient for pregnancy expulsion. Early in pregnancy, there is little increase in effectiveness after the second dose of misoprostol [<a href="#rid69">69,70</a>], although most studies have evaluated regimens of three to five doses [<a href="#rid36">36</a>]. As an example, in one randomized trial including 125 patients undergoing first-trimester pregnancy termination with misoprostol alone, effectiveness after a second or third dose was similar (86 and 88 percent, respectively) [<a href="#rid70">70</a>].</p><p>Data on second-trimester medical terminations with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> show that multiple compared with single doses are highly effective [<a href="#rid25">25,55,56</a>]. As noted above, recommended doses are lower than doses used earlier in pregnancy since the uterus is more sensitive to misoprostol and the risk of rupture appears greater. The need for repeat doses is based on lack of relevant clinical signs of progression (eg, insufficient uterine activity or cervical dilation).</p><p class="headingAnchor" id="H4093637801"><span class="h2">Side effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> is a safe and well-tolerated medication [<a href="#rid71">71</a>]. When side effects do occur, they are generally transient and self limiting; such side effects may include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – Gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common adverse effects of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> [<a href="#rid71">71</a>]. The majority of cases can be managed expectantly or with antiemetic or antidiarrheal medication. Such symptoms have been observed with all four routes of administration; severity may be dose and interval dependent (ie, higher doses and shorter dosing intervals may lead to increased symptoms) [<a href="#rid36">36,49,72</a>].</p><p></p><p class="bulletIndent1">Pretreatment with analgesics and antidiarrheal medications may slightly reduce the severity of gastrointestinal adverse effects. In a non-concurrent cohort study including 200 patients undergoing pregnancy termination at ≤56 days with vaginal administered <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> (800 mcg), pretreatment with <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> 4 mg and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> 500 mg compared with no pretreatment led to a reduction in incidence of diarrhea (23 versus 44 percent, odds ratio [OR] 0.38, 95% CI 0.2–0.7) but similar incidence of vomiting [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever</strong> – Fever, in the absence of infection, is a common effect of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> in patients undergoing first-trimester abortion [<a href="#rid35">35,36,74</a>]. It is more common with sublingual or oral administration and is dependent on dose and frequency of administration. At least one case of severe hyperthermia (41.9°C/107.4°F) in a patient who received misoprostol for postpartum hemorrhage prophylaxis has been reported [<a href="#rid75">75</a>]. Fever associated with misoprostol should subside within several hours, and antipyretics and cold compresses may be used as needed. If fever persists beyond 24 hours, the patient should be evaluated for infection (eg, infected retained products of conception).</p><p></p><p>In addition, patients who administer <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> alone compared with combined therapy may experience more fever, chills, and pain, likely because of the need for higher and repeated doses [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H3729701438"><span class="h2">Teratogenicity</span><span class="headingEndMark"> — </span>The teratogenic risk of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> appears to be low and generally limited to early first-trimester exposure [<a href="#rid77">77,78</a>]. Despite the low risk, patients who do not abort after induction with misoprostol in the first half of the first trimester should be counseled about the risk of fetal malformation (eg, Moebius syndrome, limb deformities) with an ongoing pregnancy. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Teratogenicity'</a>.)</p><p>No harmful effects have been noted among infants exposed to <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> in breast milk. While misoprostol is excreted transiently and at low levels in human breast milk [<a href="#rid79">79</a>], and levels appear to rise and decline within three to five hours of administration [<a href="#rid35">35,79</a>], patients should be informed that breastfeeding can continue without interruption [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H1616410081"><span class="h1">EFFICACY</span><span class="headingEndMark"> — </span>A combined regimen of <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> is more effective than misoprostol alone [<a href="#rid70">70,81</a>], but the misoprostol-only regimen is a reasonable option in settings where mifepristone is not available. </p><p>Rates of successful medical abortion with single-agent <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> vary depending on the dose and timing of administration. In a meta-analysis of 42 studies (27 observational studies and 15 randomized trials) including over 12,800 patients with gestations up to 13 weeks (mean 9 weeks) gestation undergoing medication abortion with single-agent misoprostol (typically 800 mcg vaginally), the pooled success rate (defined as not requiring surgical uterine evacuation) was 78 percent (95% CI 74-81 percent) [<a href="#rid82">82</a>]. Studies using protocols that allowed for ≥3 doses (maximum six doses) reported higher success rates. Beyond 13 weeks, reported success rates with repeat doses of misoprostol range from 80 to 90 percent [<a href="#rid33">33</a>]. </p><p>Other regimens (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> plus <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, other prostaglandins [<a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a>, carboprost]) are less effective than misoprostol-only and misoprostol plus <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> regimens and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Methotrexate-based regimens'</a> and  <a class="medical medical_review" href="/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination", section on 'Type of prostaglandin'</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>In many instances, no follow-up is needed for patients who experience complete expulsion of the pregnancy. A follow-up visit may be helpful for patients who experience prolonged heavy bleeding, pain, fever or, conversely, no bleeding at all. As routine follow-up visits are not mandatory, patients should be counseled prior to the procedure regarding warning signs and when to call their provider. (See <a class="local">'Planning and preparation'</a> above.)</p><p>Specific follow-up details, as they relate to trimester, are discussed separately. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Postprocedure considerations'</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Medical termination of pregnancy with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> alone is a safe procedure and the risk of a major complication is low. </p><p>In the systematic review including over 12,800 patients treated with single agent <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> discussed above (see <a class="local">'Efficacy'</a> above), transfusion or hospitalization for abortion-related complications was uncommon (0.7 percent) [<a href="#rid82">82</a>]. No deaths or ectopic pregnancies were reported. While serious infection and deaths have been reported (eg, Clostridia-associated fatal toxic shock syndrome), such cases are rare and occurred mostly in the early 2000s [<a href="#rid83">83-90</a>]. (See  <a class="medical medical_review" href="/d/html/5539.html" rel="external">"Toxic shock syndrome due to Paeniclostridium sordellii", section on 'Abortion'</a>.) </p><p>Complications of medication abortion with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> alone are similar to those of medication abortion with misoprostol plus <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and are described in detail separately. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H340901847"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109182.html" rel="external">"Society guideline links: Pregnancy termination"</a>.)</p><p class="headingAnchor" id="H38"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8400.html" rel="external">"Patient education: Abortion (pregnancy termination) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H39"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical application </strong>–<strong> </strong>A combined regimen of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> and <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> is generally considered the gold standard for medication abortion since it is more effective than single-agent regimens. This is discussed in detail separately. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Efficacy'</a>.). </p><p></p><p class="bulletIndent1">However, misoprostol-alone regimens may be the treatment of choice in settings where <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> is not available or is too costly. <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> is commonly used for second-trimester pregnancy termination in the United States and many other parts of the world. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination", section on 'Protocol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a uterine scar</strong> – Presence of a uterine scar is <strong>not</strong> a contraindication for <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>. While case reports have described uterine rupture during first- and second-trimester pregnancy termination with misoprostol, uterine rupture can also occur in patients without a uterine scar. As pregnancy advances, regimens with lower cumulative misoprostol doses (ie, lowest dose, longest dosing interval, lowest number or total doses) or a surgical procedure (ie, uterine aspiration, D&amp;E) may be preferred, especially for patients with a history of multiple cesarean births or with certain types of uterine incisions (eg, classical, T-shaped, transfundal). (See <a class="local">'Patients with a uterine scar'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Accepted regimens for misoprostol-only medication abortion are listed in the table  (<a class="graphic graphic_table graphicRef128440" href="/d/graphic/128440.html" rel="external">table 3</a>). (See <a class="local">'Accepted regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If fetal and placental expulsion has not occurred after 24 to 40 hours of the first dose of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, we suggest either repeating the protocol or performing a uterine evacuation procedure rather than using alternative uterotonics (eg, other prostaglandins, <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Accepted regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients beyond 12 weeks of gestation, expulsion of the placenta usually occurs shortly after the fetus is delivered but may take as long as 30 minutes to four hours from delivery of the fetus. If the placenta still does not deliver or the patient starts bleeding excessively, manual or surgical removal of the placenta may be required. (See <a class="local">'Management of placenta'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Gastrointestinal symptoms (nausea, vomiting, diarrhea) and fever are the most common side effects of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>. These are generally transient and self-limiting. Pretreatment with analgesics, antipyretics, and/or antidiarrheal medications may be used as needed. (See <a class="local">'Side effects'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– Medical termination of pregnancy with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> alone is a safe procedure and the risk of a major complication is low. Such complications are similar to those undergoing medication abortion with misoprostol plus <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and are described in detail separately. (See <a class="local">'Complications'</a> above and  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Rates of successful medication abortion with single-agent <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> vary depending on the dose and timing of administration. When given at up to 13 weeks of gestation, the success rate is 78 percent (ie, 22 percent of treated patients require surgical uterine evacuation). Reported success rates with repeat doses of misoprostol given beyond 13 weeks range from 80 to 90 percent. These estimates are considerably lower than with a combined regimen of <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and misoprostol. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling and</strong> <strong>follow-up</strong> – Patients should be counseled prior to the procedure regarding warning signs and when to call their provider  (<a class="graphic graphic_table graphicRef126344" href="/d/graphic/126344.html" rel="external">table 2</a>). (See <a class="local">'Planning and preparation'</a> above.)</p><p></p><p class="bulletIndent1">Routine follow-up is usually not necessary for patients who experience complete expulsion of the pregnancy. Specific follow-up details, as they relate to trimester, are discussed separately. (See <a class="local">'Follow-up'</a> above and  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Postprocedure considerations'</a>.)</p><p></p><p class="headingAnchor" id="H2428459676"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Wesley Clark, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Borgatta L, Mullally B, Vragovic O, et al. Misoprostol as the primary agent for medical abortion in a low-income urban setting. Contraception 2004; 70:121.</a></li><li><a class="nounderline abstract_t">Aldrich T, Winikoff B. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. BJOG 2007; 114:555.</a></li><li><a class="nounderline abstract_t">Wiebe ER, Trouton KJ, Lima R. Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. Int J Gynaecol Obstet 2006; 95:286.</a></li><li class="breakAll">United Nations Development Program/United Nations Fund for Population Activities/World Health Organization/World Bank Special Program of Research Development and Research Training in Human Reprod. Annual Technical Report, 1997. World Health Organization, Geneva, Switzerland 1998.</li><li><a class="nounderline abstract_t">Saha S, Bal R, Ghosh S, Krishnamurthy P. Medical abortion in late second trimester--a comparative study with misoprostol through vaginal versus oral followed by vaginal route. J Indian Med Assoc 2006; 104:81.</a></li><li><a class="nounderline abstract_t">Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 2007; 13:37.</a></li><li><a class="nounderline abstract_t">Ngai SW, Tang OS, Ho PC. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Pract Res Clin Obstet Gynaecol 2003; 17:765.</a></li><li><a class="nounderline abstract_t">Kim JO, Han JY, Choi JS, et al. Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report. Reprod Toxicol 2005; 20:575.</a></li><li><a class="nounderline abstract_t">Daskalakis GJ, Mesogitis SA, Papantoniou NE, et al. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. BJOG 2005; 112:97.</a></li><li><a class="nounderline abstract_t">Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol 2005; 105:352.</a></li><li><a class="nounderline abstract_t">El-Matary A, Navaratnarajah R, Economides DL. Ultrasound diagnosis of uterine dehiscence following mifepristone/misoprostol regime in early second trimester termination. J Obstet Gynaecol 2006; 26:578.</a></li><li><a class="nounderline abstract_t">Mazouni C, Provensal M, Porcu G, et al. Termination of pregnancy in patients with previous cesarean section. Contraception 2006; 73:244.</a></li><li><a class="nounderline abstract_t">Nayki U, Taner CE, Mizrak T, et al. Uterine rupture during second trimester abortion with misoprostol. Fetal Diagn Ther 2005; 20:469.</a></li><li><a class="nounderline abstract_t">Mazzone ME, Woolever J. Uterine rupture in a patient with an unscarred uterus: a case study. WMJ 2006; 105:64.</a></li><li><a class="nounderline abstract_t">Al-Hussaini TK. Uterine rupture in second trimester abortion in a grand multiparous woman. A complication of misoprostol and oxytocin. Eur J Obstet Gynecol Reprod Biol 2001; 96:218.</a></li><li><a class="nounderline abstract_t">Syed S, Noreen H, Kahloon LE, Chaudhri R. Uterine rupture associated with the use of intra-vaginal misoprostol during second-trimester pregnancy termination. J Pak Med Assoc 2011; 61:399.</a></li><li><a class="nounderline abstract_t">Cuellar Torriente M. Silent uterine rupture with the use of misoprostol for second trimester termination of pregnancy : a case report. Obstet Gynecol Int 2011; 2011:584652.</a></li><li><a class="nounderline abstract_t">Can S, Aktoz F. What is your diagnosis? J Turk Ger Gynecol Assoc 2020; 21:134.</a></li><li><a class="nounderline abstract_t">Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med 2001; 344:38.</a></li><li><a class="nounderline abstract_t">Andrikopoulou M, Lavery JA, Ananth CV, Vintzileos AM. Cervical ripening agents in the second trimester of pregnancy in women with a scarred uterus: a systematic review and metaanalysis of observational studies. Am J Obstet Gynecol 2016; 215:177.</a></li><li><a class="nounderline abstract_t">Daskalakis G, Papantoniou N, Mesogitis S, et al. Sonographic findings and surgical management of a uterine rupture associated with the use of misoprostol during second-trimester abortion. J Ultrasound Med 2005; 24:1565.</a></li><li class="breakAll">Mifeprex (mifepristone) Information. US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm (Accessed on November 16, 2022).</li><li><a class="nounderline abstract_t">Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013; 121:186.</a></li><li class="breakAll">Medication abortion up to 70 days of gestation. ACOG Practice Bulletin No. 225. American College of Obstetricians and Gynecologists. Obstet Gynecol 2020;136:e31–47. Reaffirmed 2023.</li><li class="breakAll">Science Says: Summaries of research for members and advocates. Society of Family Planning. Available at: https://societyfp.org/research/science-says/ (Accessed on March 06, 2023).</li><li class="breakAll">World Health Organization. Abortion Care Guideline (2022). https://apps.who.int/iris/bitstream/handle/10665/349316/9789240039483-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on November 10, 2022).</li><li><a class="nounderline abstract_t">Morris JL, Winikoff B, Dabash R, et al. FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynaecol Obstet 2017; 138:363.</a></li><li class="breakAll">National Abortion Federation. 2022 Clinical Policy Guidelines for Abortion Care. In: NAF, 
editor. Washington, DC: National Abortion Federation; 2022.</li><li><a class="nounderline abstract_t">Raymond EG, Mark A, Grossman D, et al. Medication abortion with misoprostol-only: A sample protocol. Contraception 2023; 121:109998.</a></li><li><a class="nounderline abstract_t">Wong KS, Ngai CS, Yeo EL, et al. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000; 15:709.</a></li><li><a class="nounderline abstract_t">Herabutya Y, Chanrachakul B, Punyavachira P. A randomised controlled trial of 6 and 12 hourly administration of vaginal misoprostol for second trimester pregnancy termination. BJOG 2005; 112:1297.</a></li><li><a class="nounderline abstract_t">Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002; 186:470.</a></li><li><a class="nounderline abstract_t">Ho PC, Blumenthal PD, Gemzell-Danielsson K, et al. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 2007; 99 Suppl 2:S178.</a></li><li><a class="nounderline abstract_t">Green J, Borgatta L, Sia M, et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 2007; 76:310.</a></li><li><a class="nounderline abstract_t">Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007; 99 Suppl 2:S160.</a></li><li><a class="nounderline abstract_t">Faúndes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. Int J Gynaecol Obstet 2007; 99 Suppl 2:S172.</a></li><li><a class="nounderline abstract_t">Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90:88.</a></li><li><a class="nounderline abstract_t">Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332.</a></li><li><a class="nounderline abstract_t">Danielsson KG, Marions L, Rodriguez A, et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 1999; 93:275.</a></li><li><a class="nounderline abstract_t">Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur J Obstet Gynecol Reprod Biol 2005; 123:87.</a></li><li><a class="nounderline abstract_t">Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005; 71:22.</a></li><li><a class="nounderline abstract_t">Meckstroth KR, Whitaker AK, Bertisch S, et al. Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol 2006; 108:582.</a></li><li><a class="nounderline abstract_t">Blanchard K, Shochet T, Coyaji K, et al. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception 2005; 72:91.</a></li><li><a class="nounderline abstract_t">Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 2008; 112:1303.</a></li><li><a class="nounderline abstract_t">Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005; 72:328.</a></li><li><a class="nounderline abstract_t">Zhang J, Zhou K, Shan D, Luo X. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2022; 5:CD002855.</a></li><li class="breakAll">World Health Organization (WHO). Medical management of abortion. 2018. https://www.who.int/reproductivehealth/publications/medical-management-abortion/en/.</li><li><a class="nounderline abstract_t">Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. Hum Reprod 2002; 17:654.</a></li><li><a class="nounderline abstract_t">von Hertzen H, Piaggio G, Huong NT, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet 2007; 369:1938.</a></li><li><a class="nounderline abstract_t">Bhattacharjee N, Saha SP, Ghoshroy SC, et al. A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 2008; 48:165.</a></li><li><a class="nounderline abstract_t">Caliskan E, Dilbaz S, Doger E, et al. Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation. J Reprod Med 2005; 50:173.</a></li><li><a class="nounderline abstract_t">Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 2004; 111:1001.</a></li><li><a class="nounderline abstract_t">von Hertzen H, Piaggio G, Wojdyla D, et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 2009; 24:106.</a></li><li><a class="nounderline abstract_t">Ganguly RP, Saha SP, Mukhopadhyay S, et al. A comparative study on sublingual versus oral and vaginal administration of misoprostol for late first and early second trimester abortion. J Indian Med Assoc 2010; 108:283.</a></li><li><a class="nounderline abstract_t">Cabrera Y, Fernández-Guisasola J, Lobo P, et al. Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: a meta-analysis. Aust N Z J Obstet Gynaecol 2011; 51:158.</a></li><li><a class="nounderline abstract_t">Wildschut H, Both MI, Medema S, et al. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev 2011; :CD005216.</a></li><li><a class="nounderline abstract_t">Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet 2012; 118:166.</a></li><li><a class="nounderline abstract_t">Ngoc NT, Blum J, Raghavan S, et al. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception 2011; 83:410.</a></li><li><a class="nounderline abstract_t">Kapp N, Borgatta L, Stubblefield P, et al. Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol 2007; 110:1304.</a></li><li><a class="nounderline abstract_t">Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception 2006; 73:420.</a></li><li><a class="nounderline abstract_t">Ellis SC, Kapp N, Vragpvoc O, Borgata L. Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion. Contraception 2010; 81:441.</a></li><li><a class="nounderline abstract_t">Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. Contraception 2006; 74:26.</a></li><li><a class="nounderline abstract_t">Sheldon WR, Durocher J, Dzuba IG, et al. Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial. Contraception 2019; 99:272.</a></li><li><a class="nounderline abstract_t">Borgatta L, Chen AY, Vragovic O, et al. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 2005; 72:358.</a></li><li><a class="nounderline abstract_t">Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003; 101:1294.</a></li><li><a class="nounderline abstract_t">Liaquat NF, Javed I, Shuja S, et al. Therapeutic termination of second trimester pregnancies with low dose misoprostol. J Coll Physicians Surg Pak 2006; 16:464.</a></li><li><a class="nounderline abstract_t">Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J Obstet Gynaecol 2003; 23:407.</a></li><li><a class="nounderline abstract_t">Feldman DM, Borgida AF, Rodis JF, et al. A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination. Am J Obstet Gynecol 2003; 189:710.</a></li><li><a class="nounderline abstract_t">Carbonell JL, Varela L, Velazco A, Fernández C. The use of misoprostol for termination of early pregnancy. Contraception 1997; 55:165.</a></li><li><a class="nounderline abstract_t">Jain JK, Dutton C, Harwood B, et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002; 17:1477.</a></li><li><a class="nounderline abstract_t">Baird DT. Medical abortion in the first trimester. Best Pract Res Clin Obstet Gynaecol 2002; 16:221.</a></li><li><a class="nounderline abstract_t">Honkanen H, Piaggio G, Hertzen H, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG 2004; 111:715.</a></li><li><a class="nounderline abstract_t">Jain JK, Harwood B, Meckstroth KR, Mishell DR. Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. Contraception 2001; 63:217.</a></li><li><a class="nounderline abstract_t">Carbonell JL, Velazco A, Varela L, et al. Misoprostol for abortion at 9-12 weeks' gestation in adolescents. Eur J Contracept Reprod Health Care 2001; 6:39.</a></li><li><a class="nounderline abstract_t">Durocher J, Bynum J, León W, et al. High fever following postpartum administration of sublingual misoprostol. BJOG 2010; 117:845.</a></li><li><a class="nounderline abstract_t">Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 2000; 15:2205.</a></li><li><a class="nounderline abstract_t">Vauzelle C, Beghin D, Cournot MP, Elefant E. Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. Reprod Toxicol 2013; 36:98.</a></li><li><a class="nounderline abstract_t">da Silva Dal Pizzol T, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol 2006; 22:666.</a></li><li><a class="nounderline abstract_t">Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am J Obstet Gynecol 2004; 191:2168.</a></li><li class="breakAll">https://5aa1b2xfmfh2e2mk03kk8rsx-wpengine.netdna-ssl.com/wp-content/uploads/2020_CPGs.pdf.</li><li><a class="nounderline abstract_t">Allanson ER, Copson S, Spilsbury K, et al. Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial. Obstet Gynecol 2021; 137:801.</a></li><li><a class="nounderline abstract_t">Raymond EG, Harrison MS, Weaver MA. Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review. Obstet Gynecol 2019; 133:137.</a></li><li><a class="nounderline abstract_t">Philip NM, Winikoff B, Moore K, Blumenthal P. A consensus regimen for early abortion with misoprostol. Int J Gynaecol Obstet 2004; 87:281.</a></li><li><a class="nounderline abstract_t">Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception 2004; 70:183.</a></li><li><a class="nounderline abstract_t">Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005; 353:2352.</a></li><li><a class="nounderline abstract_t">Sinave C, Le Templier G, Blouin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002; 35:1441.</a></li><li><a class="nounderline abstract_t">Meites E, Zane S, Gould C, C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med 2010; 363:1382.</a></li><li><a class="nounderline abstract_t">Couzin J. infectious disease. RU-486-linked deaths open debate about risky bacteria. Science 2006; 312:986.</a></li><li><a class="nounderline abstract_t">Winikoff B. Clostridium sordellii infection in medical abortion. Clin Infect Dis 2006; 43:1447.</a></li><li><a class="nounderline abstract_t">Aronoff DM, Hao Y, Chung J, et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J Immunol 2008; 180:8222.</a></li></ol></div><div id="topicVersionRevision">Topic 5434 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288216" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Misoprostol as the primary agent for medical abortion in a low-income urban setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17439563" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997301" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Misoprostol alone vs. methotrexate followed by misoprostol for early abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997301" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Misoprostol alone vs. methotrexate followed by misoprostol for early abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856588" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Medical abortion in late second trimester--a comparative study with misoprostol through vaginal versus oral followed by vaginal route.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050523" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mid-trimester induced abortion: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972013" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prostaglandins for induction of second-trimester termination and intrauterine death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982851" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Misoprostol for second trimester pregnancy termination in women with prior caesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684164" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000517" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ultrasound diagnosis of uterine dehiscence following mifepristone/misoprostol regime in early second trimester termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16472563" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Termination of pregnancy in patients with previous cesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113576" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Uterine rupture during second trimester abortion with misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628979" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Uterine rupture in a patient with an unscarred uterus: a case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384812" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Uterine rupture in second trimester abortion in a grand multiparous woman. A complication of misoprostol and oxytocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21465985" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Uterine rupture associated with the use of intra-vaginal misoprostol during second-trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765835" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Silent uterine rupture with the use of misoprostol for second trimester termination of pregnancy : a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31298512" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : What is your diagnosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136959" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Misoprostol and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27018469" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cervical ripening agents in the second trimester of pregnancy in women with a scarred uterus: a systematic review and metaanalysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239663" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sonographic findings and surgical management of a uterine rupture associated with the use of misoprostol during second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239663" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sonographic findings and surgical management of a uterine rupture associated with the use of misoprostol during second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28643396" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28643396" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36849033" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Medication abortion with misoprostol-only: A sample protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686224" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16101611" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomised controlled trial of 6 and 12 hourly administration of vaginal misoprostol for second trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904609" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961566" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900443" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intervention rates for placental removal following induction abortion with misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17963768" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17961570" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9207820" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Absorption kinetics of misoprostol with oral or vaginal administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821273" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacokinetics of different routes of administration of misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9932569" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison between oral and vaginal administration of misoprostol on uterine contractility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260342" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639067" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of misoprostol plasma concentrations following buccal and sublingual administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946218" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Misoprostol administered by epithelial routes: Drug absorption and uterine response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16022846" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Misoprostol alone for early abortion: an evaluation of seven potential regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037040" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246656" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35608608" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Medical methods for first trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35608608" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Medical methods for first trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870118" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560446" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366490" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841929" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized comparison of 3 misoprostol protocols for abortion induction at 13-20 weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327617" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794161" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21121402" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A comparative study on sublingual versus oral and vaginal administration of misoprostol for late first and early second trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21466519" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249669" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Medical methods for mid-trimester termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22682768" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477682" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055725" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mifepristone in second-trimester medical abortion: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16531179" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20399952" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781256" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30831103" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246662" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798539" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827957" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Therapeutic termination of second trimester pregnancies with low dose misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12881083" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Second-trimester pregnancy termination: comparison of three different methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14526299" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9115005" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The use of misoprostol for termination of early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042265" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12041964" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Medical abortion in the first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198763" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376649" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11334475" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Misoprostol for abortion at 9-12 weeks' gestation in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406228" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : High fever following postpartum administration of sublingual misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11006200" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23207166" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16750609" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592308" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Misoprostol versus methylergometrine: pharmacokinetics in human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592308" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Misoprostol versus methylergometrine: pharmacokinetics in human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831935" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30531568" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548409" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A consensus regimen for early abortion with misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15325886" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Infection after medical abortion: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319384" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439811" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20879895" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fatal Clostridium sordellii infections after medical abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16709757" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : infectious disease. RU-486-linked deaths open debate about risky bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083019" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clostridium sordellii infection in medical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18523288" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
